Evaluation of drug treatment in irritable bowel syndrome

British Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2003, Pages 362-369

  Talley, Nicholas J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alosetron; Antidepressants; Antispasmodics; Irritable bowel syndrome; Pharmacological methods; Serotonin; Tegaserod

Indexed keywords

ALPHA GALACTOSIDASE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATROPINE; BENZODIAZEPINE DERIVATIVE; BISACODYL; BULKING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CHARCOAL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CROMOGLYCATE DISODIUM; DANTRON; DESIPRAMINE; FLUPHENAZINE; LAXATIVE; MEBEVERINE; NORTRIPTYLINE; PEPPERMINT OIL; PHENETHYLAMINE DERIVATIVE; PHENOLPHTHALEIN; PINAVERIUM; RICINOLEIC ACID; SEROTONIN UPTAKE INHIBITOR; SIMETHICONE; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNINDEXED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIETARY FIBER; DRUG EFFICACY; DRUG MEGADOSE; DYSPEPSIA; EVALUATION; HUMAN; INSOMNIA; IRRITABLE COLON; ISCHEMIC COLITIS; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDIARRHEALS; CATHARTICS; COLONIC DISEASES, FUNCTIONAL; DRUG DESIGN; FORECASTING; HUMANS; PARASYMPATHOLYTICS; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0141505019     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01966.x     Document Type: Review

References (94)

1. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555-564.
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131.
3. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122: 1701-1714.
4. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38: 1569-1580.
5. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171-1185.
6. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome. Long-term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122: 107-112.
7. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122: 2032-2048.
8. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity. Facts, speculations, challenges. Gut 2001; 48: 125-131.
9. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-1893.
10. Monnikes H, Tebbe JJ, Hildebrandt M, Arck P, Osmanoglou E, Rose M, Klapp B, Wiedenmann B, Heymann-Monnikes I. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis 2001; 19: 201-211.
11. Camilleri M, Prather CM. The irritable bowel syndrome: Mechanisms and a practical approach to management. Ann Intern Med 1992; 116: 1001-1008.
12. Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome. Relationship of disorders in the transit of single solid meal to symptom patterns. Gut 1983; 24: 405-411.
13. Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology 2002; 123: 700-706.
14. Gwee KA, Leong VL, Graham C. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406.
15. Talley NJ. Treatment of the irritable bowel syndrome. In Therapy of Digestive Disorders - a Companion to Sleisenger and Fordtran's Gastrointestinal and Liver Disease, eds Wolfe MM, et al. Philadelphia, W.B. Saunders, 2000.
16. Klein KB. Controlled treatment trials in the irritable bowel syndrome. A critique. Gastroenterol 1988; 95: 232-241.
17. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 272-282.
18. Northcutt AN, Mangel AW, Hamm LR, et al. Persistent placebo response during a year-long controlled trial of IBS treatment. Gastroenterology 2001; 120: A640.
19. Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, Battaglia G, Desideri S, Faedo A, Marzolino C, Tonon A, Ermani M, Leandro G. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci 2002; 47: 1697-1704.
20. Soltoft J, Krag B, Gudmand-Hoyer E, et al. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. Lancet 1976; i: 270-272.
21. Manning AP, Heaton KW, Harvey RF. Wheat fibre and irritable bowel syndrome. A controlled trial. Lancet 1977; ii: 417-418.
22. Longstreth GF, Fox DD, Youkeles L, et al. Psyllium therapy in the irritable bowel syndrome. A double-blind trial. Ann Intern Med 1981; 95: 53-56.
23. Ornstein MH, Littlewood ER, Baird IM, et al. Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J 1981; 282: 1353-1356.
24. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1979; 1: 376-378.
25. Cann PA, Read NWH, Holdsworth CD. What is the benefit of coarse bran in patients with irritable bowel syndrome? Gut 1984; 25: 168-171.
26. Arffmann S, Andersen JR, Hegnhoj J, et al. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. Scand J Gastroenterol 1985; 20: 295-298.
27. Kruis W, Weinzeierl M, Schussler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986; 34: 196-201.
28. Lucey MR, Clark ML, Lowndes JO, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double-blind placebo controlled crossover study. Gut 1987; 28: 221-225.
29. Cook IJ, Irvine EJ, Campbell D, et al. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology 1990; 98: 66-72.
30. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-147.
31. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol 1998; 93: 2184-2190.
32. Stefanini GF, Prati E, Albini MC, et al. Oral disodium cromoglycate treatment of irritable bowel syndrome. An open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992; 87: 55-57.
33. Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gasbarrini G. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995; 30: 535-541.
34. Ganiats TG, Norcross WA, Halverson AL, et al. Does beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract 1994; 39: 441-445.
35. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510.
36. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-361.
37. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3: 153-156.
38. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J 1965; 2: 848-851.
39. Tasman-Jones C. Mebeverine in patients with the irritable colon syndrome. Double blind study. NZ Med J 1973; 77: 232-235.
40. Nash P, Gould SR, Barnardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract 1986; 40: 292-293.
41. Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome. A multicentre trial. Br J Clin Pract 1984; 38: 394-398.
42. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998; 93: 1131-1135.
43. Passaretti S, Guslandi M, Imbimbo BO, et al. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1989; 3: 267-276.
44. Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide. A double blind placebo controlled clinical trial. Gut 1990; 31: 355-358.
45. Centonze V, Imbimbo BP, Campanozzi F, et al. Oral cimetropium bromide, a new antimuscarinic drug for long term treatment of irritable bowel syndrome. Am J Gastroenterol 1988; 83: 1262-1266.
46. Levy C, Charbonnier A, Cachin M. Bromure de pinaverium et colopathie fonctionnelle. Sem Hop Pris (Ther) 1977; 53: 372-374.
47. Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. J Int Med Res 1979; 7: 231-234.
48. Fielding JR. Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J 1980; 73: 377-379.
49. Luttecke K. A trial of trimebutine in spastic colon. J Int Med Res 1978; 6: 86-88.
50. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome. A five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 409-416.
51. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
52. Greenbaum DA, Mayle JE, Vanegeren LE, et al. The effects of desipramine on IBS compared with atropine and placebo. Dig Dis Sci 1987; 32: 257-266.
53. Ritchie JA, Truelove SC. Comparison of various treatments for irritable bowel syndrome. Br Med J 1980; 281: 1317-1319.
54. Lancaster-Smith MJ, Prout BJ, Pinto T, et al. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982; 66: 33-41.
55. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1982; 17: 871-875.
56. Myren J, Lovland B, Larssen S-E, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19: 835-843.
57. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-behavioral therapy versus education and desipramme versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.
58. Gorard DA, Libby GW, Farthing MJ. Effect of tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40: 86-95.
59. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 159-166.
60. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson G. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303-317.
61. Kuiken SD, Tytgat GNJ, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo controlled trial. Clin Gastroenterol Hep 2003; 1: 219-228.
62. Baume P, Buthbert J. The effect of medazepam in relieving symptoms of gastrointestinal distress. Aust NZ J Med 1973; 3: 457-460.
63. Tack J. Functional dyspepsia: Impaired fundic accommodation. Curr Treat Options Gastroenterol 2000; 3: 287-294.
64. Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002; 47: 2222-2230.
65. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001; 44: 1201-1209.
66. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-468.
67. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984; 29: 239-247.
68. Lavo B, Stenstam M, Nielsen A-L. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol Supplement 1987; 130: 77-80.
69. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Supplement 1987; 130: 81-84.
70. Luman W, Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption. Long-term outcome. Eur J Gastroenterol Hepatol 1995; 7: 641-645.
71. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277-289.
72. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-2068.
73. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P. Tegaserod, a 5-HT (4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-1666.
74. Kamm MA. Review article: the complexity of drug developments in irritable bowel syndrome. Aliment Pharmacol Thor 2002; 16: 343-351.
75. Delvaux M, Louvel D, Mamet J-P, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-855.
76. Camilleri M, Bortcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of Alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-1040.
77. Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E, Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-2670.
78. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-1740.
79. Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-1427.
80. Lievre M. Alosetron for irritable bowel syndrome. Br Med J 2002; 325: 555-556.
81. Cann PA, Read NW, Holdsworth CD. Oral domperidone. Double blind comparison with placebo in irritable bowel syndrome. Gut 1983; 24: 1135-1140.
82. Fielding JF. Timolol treatment in the irritable bowel syndrome. Digestion 1981; 22: 155-158.
83. McIntyre AS, Burnham WR, Thompson DG. Atenolol in irritable bowel syndrome (letter). Lancet 1988; i: 67.
84. Greenbaum DS, Ferguson RK, Kater LA, et al. A controlled therapeutic study of the irritable bowel syndrome. Effect of diphenylhydantoin. N Engl J Med, 1973; 288: 13-16.
85. Talley NJ, Turner I, Middleton WRJ. Somatostatin and symptomatic relief of irritable bowel syndrome (letter) Lancet 1987; ii: 1144.
86. Mathias JR, Clench MH, Roberts PH, Reeves-Darby VG. Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow up after double-blind, placebo-controlled study. Dig Dis Sci 1994; 39: 1163-1170.
87. Mathias JR, Clench MH, Reeves-Darby VG, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci 1994; 39: 1115-1162.
88. Cann PA, Rovati LC, Smart HL, et al. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicentre clinical study. Ann N Y Acad Sci 1994; 713: 449-450.
89. Talley NJ. Pharmacologic therapy of the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-758.
90. Farthing MJG. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Bailliere's Clin Gastroenterol 1999; 13: 461-471.
91. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238.
92. Pimental M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506.
93. Pimental M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-419.
94. Viramontes BE, Malcolm A, Camilleri M, Szarka LA, McKinzie S, Burton DD, Zinsmeister AR. Effects of an alpha (2) -adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1468-G1476.